Last reviewed · How we verify
DTPw-HBV/Hib-MenAC conjugate vaccine — Competitive Intelligence Brief
phase 3
Combination conjugate vaccine
Immunology / Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
DTPw-HBV/Hib-MenAC conjugate vaccine (DTPw-HBV/Hib-MenAC conjugate vaccine) — GlaxoSmithKline. This combination vaccine stimulates immune responses against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and Neisseria meningitidis serogroups A and C through conjugate technology.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DTPw-HBV/Hib-MenAC conjugate vaccine TARGET | DTPw-HBV/Hib-MenAC conjugate vaccine | GlaxoSmithKline | phase 3 | Combination conjugate vaccine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Combination conjugate vaccine class)
- GlaxoSmithKline · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DTPw-HBV/Hib-MenAC conjugate vaccine CI watch — RSS
- DTPw-HBV/Hib-MenAC conjugate vaccine CI watch — Atom
- DTPw-HBV/Hib-MenAC conjugate vaccine CI watch — JSON
- DTPw-HBV/Hib-MenAC conjugate vaccine alone — RSS
- Whole Combination conjugate vaccine class — RSS
Cite this brief
Drug Landscape (2026). DTPw-HBV/Hib-MenAC conjugate vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/dtpw-hbv-hib-menac-conjugate-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab